Novartis Dialogue to Explore Solutions to Rise of Chronic Diseases in Developing World

The event will take place November 29 on the Novartis Campus in Basel, Switzerland and will also be webcast.

The joint dialogue event is co-hosted by Novartis Access and the Novartis Foundation, with experts from Novartis (No. 2 on the DiversityInc Top 50 Companies list), academia and nonprofit organizations speaking and attending.


It will be an opportunity to look back on the lessons learned during the first year of Novartis Access, an innovative social business approach to treat chronic diseases in lower-income countries. Speakers from both Novartis and its partners will present findings and discuss how they addressed challenges in the implementation, one year into the program.

This dialogue will also provide a broader view on how Novartis is working with other organizations to explore innovative approaches to address chronic diseases in lower income countries by both strengthening healthcare systems and improving access to medicines.

Event Details

Speakers and panelists will include representatives from the World Health Organization, PATH, Red Cross, Pink Ribbon Red Ribbon, the London School of Hygiene & Tropical Medicine and Boston University, as well as government delegates.

Joerg Reinhardt, Novartis Chairman, will also deliver a keynote address.

Improving care for chronic patients in lower-income countries: the patient journey

Friday, November 29, 2016

09:30 – 15:30 CET

Basel, Novartis Campus, Gehry auditorium

This event will be available to watch via a live webcast on November 29.

Register for the webcast here.

Series of dialogue events on access

This event will document the progress and results of Novartis Access one year after launch, in terms of country implementation, impact evaluation, and partnerships. It is part of a dialogue series with key stakeholders.

Novartis Survey Uncovers Real-World Impact of Immune Thrombocytopenia or ITP, a Rare Blood Disease, on Patients' Quality of Life

Findings from more than 1,300 patients across 13 countries showed ITP had especially high impact for many patients on emotional well-being (36%) and ability to work (28%).

Originally Published by Novartis.

Many patients with the rare blood disorder immune thrombocytopenia (ITP) find the disease has a negative impact on their everyday quality of life, according to interim results of a Novartis survey, called I-WISh, presented today at the 23rd Congress of the European Hematology Association (EHA) in Stockholm, Sweden (Abstract #PF654).

Read More Show Less

Open Resources at Novartis Help Drive Innovation

With external help from Novartis, an Argentinian researcher was able to begin his search for a new medicine for tuberculosis.

Originally Published by Novartis.

By K.E.D. Coan

"Back in Argentina, you never think of going for a real drug, but coming to Novartis completely changed what I thought was possible," says Bernardo Bazet Lyonnet, a postdoctoral researcher who first came to Novartis in 2016 as a Next Generation Scientist ( NGS). This program invites talented scientists from around the world for a bi-directional learning exchange at the Novartis campus in Basel, Switzerland.

Read More Show Less

Third Novartis Phase III trial shows Kisqali combination therapy significantly improves PFS in HR+/HER2- advanced breast cancer

"In the advanced breast cancer setting, it is important to ensure we provide patients with treatment options that increase time to disease progression while also maintaining quality of life."

Originally Published by Novartis.

Novartis announced positive results from the third Phase III trial of Kisqali® (ribociclib) in advanced or metastatic breast cancer. MONALEESA-3 showed Kisqali plus fulvestrant significantly prolonged progression-free survival (PFS) compared to fulvestrant alone in postmenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer. MONALEESA-3 is the largest phase III trial to evaluate efficacy and safety of a CDK4/6 inhibitor plus fulvestrant in multiple advanced breast cancer patient populations - first-line and second-line settings[1]. These data will be presented as an oral presentation at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago (Abstract #1000) and published simultaneously in the Journal of Clinical Oncology.

Read More Show Less

EY, Kaiser Permanente, Novartis, PwC and Sodexo have been inducted into DiversityInc's Top 50 Hall of Fame. The companies inducted into the Hall of Fame have demonstrated exceptional human capital management accomplishments and superior corporate values and culture.

Read More Show Less